Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?
- 6 August 2012
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 11 (5) , 797-801
Abstract
Introduction: The first biopharmaceuticals were developed 30 years ago. Biopharmaceuticals differ significantly from small molecule therapeutics (SMTs). Because of such differences, it was expected that classical preclinical safety evaluation procedures applied to SMTs would not predict the adverse effects of biopharmaceuticals. Therefore, until sufficient experience was gained, the preclinical safety evaluation of biopharmaceuticals was carried out on a case-by-case basis. 30 years of experience has since expanded the knowledge base in this area, in the hope to design a preclinical safety evaluation procedure suited to biopharmaceuticals. Areas covered: This review describes how the preclinical safety evaluation of biopharmaceuticals has evolved. It shows that, as result of the risk-averse behavior of regulators and industry, classical procedures were taken as starting point although state-of-the-art knowledge on biopharmaceuticals was directed towards creating a new procedure, driven by the specific properties of biopharmaceuticals. Expert opinion: Current preclinical safety evaluation guidance of biopharmaceuticals is criticized because it employs a checkbox approach. The adverse effects induced by biopharmaceuticals are on-target or immune system–induced, therefore, the preclinical safety evaluation should not be standardized, but rather driven by product specific safety concerns.Keywords
This publication has 13 references indexed in Scilit:
- Safety evaluation of biological drugs: What are toxicology studies in primates telling us?Regulatory Toxicology and Pharmacology, 2011
- Mapping the Safety Profile of BiologicalsDrug Safety, 2010
- Nonclinical development of biopharmaceuticalsDrug Discovery Today, 2009
- Safety Issues Specific to Clinical Development of Protein TherapeuticsClinical Pharmacology & Therapeutics, 2008
- Early Development of Therapeutic Biologics - PharmacokineticsCurrent Drug Metabolism, 2006
- Preclinical safety evaluation of biotechnology-derived pharmaceuticalsNature Reviews Drug Discovery, 2002
- Safety Assessment of Biotechnology-Derived Pharmaceuticals: ICH and BeyondToxicologic Pathology, 1999
- Safety evaluation of biological and biotechnology-derived medicinesToxicology, 1995
- Competing Technologies, Increasing Returns, and Lock-In by Historical EventsThe Economic Journal, 1989
- Preclinical safety testing of species-specific proteins produced with recombinant DNA-technqiuesArchives of Toxicology, 1986